Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Brain Neoplasms 5Melanoma 3Stomach Neoplasms 2Neoplasms 2Glioma 2Glioblastoma 2Breast Neoplasms 2Thyroid Diseases 1Skin Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1Ovarian Neoplasms 1Neuroma, Acoustic 1Lung Neoplasms 1Laryngeal Neoplasms 1Irritable Bowel Syndrome 1Gastrointestinal Stromal Tumors 1Gastrointestinal Diseases 1Gastroesophageal Reflux 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Cerebrovascular Disorders 1Carcinoma, Hepatocellular 1Barrett Esophagus 1Astrocytoma 1Adenomatous Polyps 1Adenolymphoma 1

Interventions

Specimen Handling 2Nivolumab 2toripalimab 1talimogene laherparepvec 1pembrolizumab 1bicalutamide 1Magnetic Resonance Spectroscopy 1Lidocaine 1Ipilimumab 1Imiquimod 1Fluorescein 1CTLA-4 Antigen 1Biopsy 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Paget Disease, Extramammary × Fluorescein × Clear all
NCT06873815 2026-01-12

A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
27 enrolled

Paget Disease, Extramammary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡